Search Tag: Johnson & Johnson

Executive Health Management

Johnson & Johnson to Split into Two Companies; Shares Rise

2021 12 Nov

Health-care giant Johnson & Johnson is splitting off its consumer division, following in the footsteps of other big drugmakers that have moved to focus on the more-profitable pharmaceutical market.   The consumer division will be separated in 18 to 24 months, the company said in a statement. The unit has been beset by lawsuits involving products... Read more

Executive Health Management

U.S. FDA Backs [email protected] COVID-19 Vaccine Boosters

2021 19 Oct

On Friday, 15 October, a U.S. FDA advisory committee unanimously recommended that all adults that received the Johnson & Johnson (J&J) COVID-19 vaccine get a booster shot at least two months after their first shot. J&J now joins Pfizer and Moderna in gaining an FDA recommendation for a booster.   Unlike the Pfizer and Moderna recommendations which... Read more

Executive Health Management

Two Doses Make Johnson & Johnson COVID-19 Vaccine 94% Effective

2021 22 Sep

In July, New York University researchers published results (Tada et. al, 2021) indicating the one-shot Johnson & Johnson (J&J) vaccine was less effective at preventing Delta variant infections. Although the study is not yet peer-reviewed, this finding is troubling given that the Delta variant now accounts for most US COVID-19 cases. Booster doses were... Read more

Executive Health Management

EMA’s Conclusion on Janssen Vaccine and Blood Clots

2021 21 Apr

The European Medicines Agency has completed its safety review for Johnson & Johnson’s COVID-19 Vaccine Janssen giving conclusions similar to those on AstraZeneca’s Vaxzevria.   You might also like: EMA announced that the single dose Covid-19 vaccine has been approved for use in individuals 18 years of age and older in the European... Read more

Executive Health Management

Vaccine Rollout: Implications of “Abundance of Caution”

2021 20 Apr

Over the last week the COVID-19 vaccine landscape has once again changed drastically, with the use of J&J’s Janssen suspended in many countries and new players attracting more attention.   You might also like: Shortages of COVID-19 vaccine supplies are being felt globally, not excluding the EU and the UK. Do companies fulfil their obligations... Read more

Executive Health Management

What’s Happening with COVID-19 Vaccine Supply?

2021 29 Mar

Shortages of COVID-19 vaccine supplies are being felt globally, not excluding the EU and the UK. Do companies fulfil their obligations and where will new manufacturing facilities be created?   You might also like: Why has AstraZeneca’s COVID-19 vaccine been the centre of attention in Europe over the past few days? Learn more... Read more

Executive Health Management

EU Regulator says “Yes” to Johnson & Johnson One-shot Vaccine

2021 11 Mar

The European Medicines Agency’s (EMA) announced today that the single dose Covid-19 vaccine has been approved for use in individuals 18 years of age and older in the European Union.   Developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) in Belgium and the Netherlands, this vaccine is the fourth to be approved by the EMA.... Read more

Executive Health Management

AZ COVID-19 Trial Continues Despite Participant’s Death

2020 23 Oct

This week has seen another COVID-19 vaccine-related incident: a volunteer in the AstraZeneca (AZ) vaccine trial in Brazil has died. Nevertheless, the trial continues as might the previously halted Johnson & Johnson’s (J&J) and the U.S. arm of AZ’s trial.   You might also like: Rushing COVID-19 Vaccine Development: Is It Justified?... Read more

Executive Health Management

J&J’s Vaccine Trial Paused

2020 13 Oct

Johnson & Johnson has announced temporarily pausing the COVID-19 vaccine candidate trials due to an unexplained illness in a study participant.   You might also like: Rushing COVID-19 Vaccine Development: Is It Justified?   As reported by STAT News, the company has informed external researchers through a document that a “passing... Read more